Pralsetinib: Targeted Therapies for RET-Fusion Positive NSCLC

lung cancer
Pralsetinib is a RET receptor tyrosine kinase inhibitor used to treat metastatic RET-driven non-small cell lung cancer. Learn more

Log In or Register as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: